

# **Carrier detection and phenotypic expression in a family with hereditary coproporphyrria**

**Naz AL Hafid**

A thesis submitted in fulfilment of the  
requirements for the Degree of Masters of  
Science (Research)

Department of Medical and Molecular  
Biosciences  
Faculty of Science,  
University of Technology, Sydney (UTS)  
NSW, Australia.  
November 2007

## Statutory Declaration

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

Naz AL Hafid

Production Note:  
Signature removed prior to publication.

Date

16/7/08

# Acknowledgements

This has been a long journey, and alas I am at the stage where I can thank all those great individuals who have helped me finish this thesis. Without the support and guidance that I have been surrounded with, this would have been impossible to complete.

I would like to thank Dr Victor Poulos and Professor Ann Simpson for supervising this project. My thanks to Dr Victor for the constant positive feedback, support and encouragement that he provided me along this journey, also for giving me the opportunity to expand my professional connections and interactions. I would like to thank Professor Ann Simpson from the University of Technology, Sydney for the academic support and supervision, and also for the ongoing guidance. I would also like to thank Professor Peter Stewart from the Royal Prince Alfred Hospital for funding the project, and providing me with financial support to present my results at the European Porphyria Initiative Conference, Rotterdam, Thank you that was an unforgettable experience.

I would like to extend a special thank you to Associate Professor Bruce Bennetts and his staff from the Molecular Genetics Department. The technical support, guidance and advice in both the practical and theoretical aspects of this project have been truly priceless. I like to thank Associate Professor Bruce Bennetts for patiently explaining the many complicated concepts of molecular genetics. To my manager Dr Kevin Carpenter from the Biochemical Genetics Department at the Children's Hospital at Westmead, I want to express my many thanks and appreciation for the professional, academic and moral support that you have given me and for being so understanding and supportive by allowing me to take time off from work – it is mainly one of the major factors that has allowed me to retain my sanity. Another person who has given me an immense level of encouragement, enthusiasm, support (both academic and professional) and feedback is Professor Bridget Wilcken from the Biochemical Genetics Department, thank you for your support.

I want to also thank Dr Bruce Lord from the Children's Hospital at Westmead, Dr Jane Young from Royal Prince Alfred Hospital for their help with designing the

Questionnaire. Also thanks to Professor Jenny Peat for help with the Statistics and use of the SPSS software. Dr Corne Biesheuvel, thank you for the help with the Statistical results and interpretations.

I want to thank my dear friends and colleagues – whose support and encouragement has been a treasured privilege; Dr Beena Devanapalli, thank you for the academic feedback and moral support and also for putting up with my endless mood swings and frustrations, Mrs Vida Khalili for the incredible moral support that you have given me, and most importantly for making me laugh at the times when things seemed impossible, and for your invaluable advice. My very close friend Simone Coupe, I want to express my appreciation for the priceless value of our friendship, for giving me unconditional moral and emotional support, for organising fun outings when I desperately needed to mingle with society, for putting me up when I was down, for listening to me and for encouraging me through it all by reminding me of our motto “Just keep it going”.

Last but not least I want to thank my parents Shireen and Baiz and my sister Zina, for whom without them I would not have reached my dreams. Without their unconditional love and support this would have been certainly impossible to achieve. I want to thank my mother for being the best mum in the world, a great teacher and a best friend at the same time. Thank you for recognising my passion in science and helping me pursue my goals. To my dad, I want to thank you for being the best dad and everything you have done for me and the unconditional love you have provided me with and for putting up with the endless questions I asked as a child. Although quiet most of the time, yet when I was in trouble, he was the first to calm me down. To my dearly loved younger sister Zina, what would have I done without you? I cannot comprehend my life without you, for the unconditional love you have given me, I feel blessed. Thank you for keeping me sane at most times and driving me insane at other times – for one need to experience both! Although you are younger than me, but I must admit, you have taught me a lot about myself. You helped me grow in everyway!



# Table of Contents

Statutory Declaration .....	ii
Acknowledgements .....	iii
Table of Contents .....	v
List of Figures .....	vii
List of Tables.....	viii
List of Abbreviations.....	ix
Publications Arising From This Thesis.....	x
ABSTRACT.....	xi
CHAPTER 1: DIAGNOSIS OF HEREDITARY COPROPORPHYRIA .....	12
1.1 Introduction .....	12
1.2 Chemical characteristics of porphyrins and porphyrinogens .....	14
1.3 The haem biosynthetic pathway.....	17
1.3.1 Formation of pyrrole structure .....	18
1.3.2 Assembly of the tetrapyrroles .....	18
1.3.3 Modification of the tetrapyrrole side chains .....	18
1.3.1.4 Oxidation of protoporphyrinogen IX to protoporphyrin IX and insertion of iron .....	20
1.4 Regulation of haem biosynthesis .....	21
1.5 Molecular characteristics of CPOX .....	22
1.6 Clinical manifestations.....	24
1.7 Dual porphyrias.....	25
1.8 Environmental factors .....	26
1.8.1 Drugs .....	27
1.8.2 Endocrine factors .....	28
1.8.3 Other factors.....	28
1.9 Metabolic defects .....	29
1.10 Molecular defects of HCP .....	29
1.11 How do environmental factors provoke an acute attack? .....	31
1.12 Diagnosis of HCP.....	34
1.13 Diagnostic methods.....	35
1.14 Penetrance of the acute porphyrias .....	37
1.15 Prognosis/treatment.....	38
1.15.1 Supportive treatment .....	39
1.15.2 Symptomatic treatment .....	39
1.16 Purpose of this project.....	41
CHAPTER 2: MATERIALS AND METHODS .....	44
2.1 Blood collection .....	44
2.2 Sample storage and handling .....	44
2.3 Equipments, reagents and materials.....	44
2.4 DNA extraction .....	45
2.4.1 Materials.....	45
2.4.2 Extraction method .....	45
2.5 Primer design .....	46
2.6 BLAT search results.....	48
2.7 Preparation of working primers .....	48
2.8 PCR .....	48
2.8.1Materials.....	48
2.8.2Method .....	49
2.9 GC-Rich PCR.....	50

2.9.1 Materials.....	50
2.9.2 Method .....	50
2.10 Polyacrylamide Gel Electrophoresis (PAGE).....	50
2.10.1 Materials.....	50
2.10.2 Reagent preparation .....	51
2.10.2.1 Ammonium persulfate (APS) 10% (w/v) .....	51
2.10.2.2 10% Acrylamide in 1xTBE.....	51
2.10.2.3 Tris-Borate EDTA (TBE) buffer.....	51
2.10.2.4 Loading dye.....	51
2.10.2.5 Ethidium bromide (2µg/mL).....	52
2.10.3 Method .....	52
2.11 PCR product treatment.....	52
2.11.1 Materials.....	52
2.11.2 Method .....	53
2.12 Preparation of treated PCR product for sequencing.....	53
2.12.1 Reagents .....	53
2.12.2 Method .....	53
2.13 Sequencing.....	53
2.13.1 Equipments and reagents.....	54
2.13.2 Sample preparation method.....	54
2.14 Sequencing analysis .....	55
2.14.1 Materials.....	55
2.14.2 Method .....	55
2.15 Questionnaire .....	56
2.15.1 Designing the questionnaire.....	56
2.16 Denaturing HPLC (dHPLC).....	58
2.16.1 Materials.....	58
2.16.2 Sample preparation method.....	58
2.16.3 Optimal temperature determination .....	59
2.17 Qualitative analysis .....	59
CHAPTER 3: RESULTS .....	60
3.1 PCR and sequencing results.....	60
3.2 Denaturing HPLC (dHPLC) results .....	67
3.3 Descriptive statistics - frequency analysis .....	68
3.4 Questionnaire and statistical analysis results.....	69
3.5 Phenotypic expressions resulting from the Q355P mutation .....	70
3.6 Summary of results .....	85
CHAPTER 4: DISCUSSION.....	86
4.1 Locating the disease causing mutation in known HCP patients .....	87
4.2 Q355P Mutation.....	87
4.3 Family screening for Q355P mutation .....	88
4.4 Biochemical results for HCP index patients .....	90
4.5 Revealing phenotypic expressions through questionnaire studies .....	91
4.6 Conclusion .....	95
APPENDIX 1 .....	98
APPENDIX 2 .....	107
APPENDIX 3 .....	116
References.....	117



# List of Figures

FIGURE 1.1: THE BASIC STRUCTURE OF PORPHYRIN, A TETRAPYRROLE STRUCTURE FORMED BY FOUR PYRROLE RINGS JOINED BY METHENE BRIDGES. ....	15
FIGURE 1.2 A TYPICAL UV-VISIBLE ABSORPTION SPECTRUM OF A PORPHYRIN .....	16
FIGURE 1.3: HAEM BIOSYNTHETIC PATHWAY. ENZYMES ARE IN RED FONTS AND INTERMEDIATES ARE IN BOXES. ....	17
FIGURE 1.4: CONVERSION OF UROPORPHYRINOGEN III TO COPROPORPHYRINOGEN III THROUGH THE SEQUENTIAL REMOVAL OF THE FOUR CARBOXYLIC GROUPS OF THE ACETIC ACID SIDE CHAINS. ....	19
FIGURE 1.5: CONVERSION OF COPROPORPHYRINOGEN III TO PROTOPORPHYRINOGEN IX.	20
FIGURE 1.6: THE HUMAN CPOX GENE AND LOCATIONS OF MUTATIONS CAUSING HCP...	31
FIGURE 1.7: FLOWCHART SHOWING THE SEQUENCE OF ACTIVITIES WHEN DRUGS ARE TAKEN AND THEIR EFFECT ON HEME AND CYTOCHROME P450. ....	32
FIGURE 3.1: CHROMATOGRAM SHOWING A NOVEL SNP DETECTED IN INDEX PATIENT 1..	61
FIGURE 3.2: CHROMATOGRAM SHOWING THE POSITION OF THE Q355P MUTATION.....	62
FIGURE 3.3: A NORMAL CHROMATOGRAM FROM EXON 5 OF THE CPOX GENE. ....	63
FIGURE 3.4: CHROMATOGRAM SHOWING THE POSITION OF THE SINGLE NUCLEOTIDE POLYMORPHISM IN EXON 5 OF THE CPOX GENE FOUND IN INDEX PATIENT THREE. ..	63
FIGURE 3.5: MULTIPLE SEQUENCE ALIGNMENTS ACROSS SOME MAMMALIAN SPECIES.....	64
FIGURE 3.7: CHROMATOGRAPHIC REPRESENTATION OF dHPLC RESULTS COMPARING FOUR PATIENTS WITH DIFFERENT GENOTYPES. ....	68
FIGURE 3.8: A GRAPHICAL REPRESENTATION OF COMMON PORPHYRIA SYMPTOMS REPORTED BY ALL PARTICIPANTS IN THE QUESTIONNAIRE STUDY. ....	72
FIGURE 3.9: COMMON PORPHYRIA SYMPTOMS IN ALL FEMALES WHO PARTICIPATED IN THE QUESTIONNAIRE. ....	74
FIGURE 3.10: A GRAPHICAL REPRESENTATION OF MALES WHO EXPERIENCED COMMON PORPHYRIA SYMPTOMS.....	75
FIGURE 3.11: A GRAPHICAL REPRESENTATION OF COMMON PORPHYRIA SYMPTOMS REPORTED BY MALES AND FEMALES WITH THE MUTATION. ....	76

**List of Tables**

TABLE 2.1: SUMMARY OF CPOX PRIMERS USED FOR PCR 47

TABLE 3.1: SUMMARY OF SEQUENCING RESULTS OBTAINED FOR ALL MEMBERS RELATED  
TO INDEX PATIENT 3. 66

TABLE 3.2: FREQUENCY OF MALES AND FEMALES WHO PARTICIPATED IN THIS STUDY..... 69

TABLE 3.3: FREQUENCY OF MALES AND FEMALES WITH THE Q355P MUTATION. .... 69

TABLE 3.4: COMMON PORPHYRIA SYMPTOMS REPORTED BY MEMBERS WHO PARTICIPATED  
IN THE QUESTIONNAIRE STUDY. 71

TABLE 3.5: COMMON PORPHYRIA SYMPTOMS REPORTED BY MEMBERS WHO PARTICIPATED  
IN THE QUESTIONNAIRE STUDY CATEGORISED BY GENDER AND MUTATION. .... 73

TABLE 3.6: A TABULAR REPRESENTATION OF PHENOTYPIC EXPRESSIONS REPORTED BY  
PATIENTS IN A FAMILY WITH HCP. 77



## List of Abbreviations

AIP	Acute Intermittent Porphyria
ALA	$\delta$ -Aminoluvilinic Acid
ALAS	$\delta$ -Aminoluvilinic Acid Synthase
APS	Ammonium Persulfate
CPOX	Coproporphyrinogen Oxidase
DHPLC	Denaturing High Performance Liquid Chromatography
ESE	Exonic Splicing Enhancers
HCP	Hereditary Coproporphyria
HMBS	Hydroxymethylbilane synthase
PAGE	Polyacrylamide Gel Electrophoresis
PBG	Porphobilinogen
PBGD	Porphobilinogen Deaminase
PCT	Porphyria Cutanea Tarda
PPOX	Protoporphyrin Oxidase
SSCP	Single Stranded Conformation Polymorphism
UROD	Uroporphobilinogen Deaminase
VP	Variegate Porphyria
WFI	Water For Injection

# Publications Arising From This Thesis

## Poster Abstracts

AL Hafid N, Poulos V, Bennetts B, Simpson A, Carpenter K, Stewart P (2007)

Mutation screening and carrier detection in a family with hereditary coproporphyrria (HCP). European Porphyrria Initiative, Rotterdam, The Netherlands.

AL Hafid N, Poulos V, Bennetts B, Simpson A, Stewart P (2006) Identification of a novel mutation in a family with hereditary coproporphyrria (HCP). 10<sup>th</sup> International Congress of Inborn Errors of Metabolism, Chiba, Japan.

Naz AL HAFID, Victor POULOS, Bruce BENNETTS, Ann M. SIMPSON, Kevin CARPENTER, Peter STEWART (2006) Mutation screening in the coproporphyrinogen oxidase gene in patients with HCP: Identification of a novel mutation. AIMS AACB Scientific Conference, Hobart, Australia. - **Won first prize for best poster.**

## Oral Presentations

Western Sydney Genetics Program (2005) – The children's Hospital at Westmead.  
The Study of Penetrance And Carrier Detection In Acute Intermittent Porphyrria.

European Porphyrria Initiative conference (2007) – Rotterdam, The Netherlands.  
Mutation screening and carrier detection in a family with hereditary coproporphyrria (HCP). European Porphyrria Initiative, Rotterdam, The Netherlands.

# ABSTRACT

## Carrier Detection and phenotypic expression in a family with hereditary coproporphyria

**Introduction:** Hereditary coproporphyria (HCP) is an autosomal dominant disorder that results from defects in the enzyme coproporphyrinogen oxidase (CPOX). A major clinical feature is neurologic damage that leads to peripheral and autonomic neuropathies and psychiatric manifestations, accompanied occasionally by cutaneous skin lesions. HCP symptoms are usually triggered by environmental factors such as drugs and hormones. However, the penetrance is low meaning that most patients remain asymptomatic most of their lives. This makes it more difficult to diagnose asymptomatic HCP patients by solely relying on biochemical methods. The aim of this study was to genetically screen carriers in a family with HCP and design a questionnaire to identify subtle porphyria symptoms.

**Methods:** Mutation screening was carried out in a family of thirty members, two of whom were symptomatic for HCP. The entire *CPOX* gene of the proband was screened for mutations. A questionnaire was designed and completed by 26 participants to review the clinical picture and life style of patients and was compared with the genetic data.

**Results:** A novel mutation was identified in exon 5 at c.1064A>C causing a substitution in amino acid 355 from glutamine to proline (p.Q355P). Sequencing results revealed that sixteen out of thirty members of this family were carriers of the mutation. Porphyrin related symptoms were noted to be as common in males as in females with the mutation.

**Conclusions:** Patients with the Q355P mutation reported more symptoms than those without the mutation. Females reportedly are more likely to exhibit acute porphyria symptoms due to hormonal factors. However, it was noted that the number of symptoms reported by males with the mutation was more than that reported by females with the mutation. In this small sample cohort, these results suggest that environmental factors rather than endocrine factors play a role in the phenotypic expression of this mutation. Carriers are at risk of acute attacks; identifying them is beneficial because they can be given prior advice of preventative measures.